

# Priscilla K Brastianos

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9322015/priscilla-k-brastianos-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

203  
papers

7,823  
citations

47  
h-index

84  
g-index

221  
ext. papers

10,954  
ext. citations

8.5  
avg, IF

6.02  
L-index

#	Paper	IF	Citations
203	Central Nervous System Metastases. <i>Hematology/Oncology Clinics of North America</i> , <b>2022</b> , 36, 161-188	3.1	2
202	Anatomy-oriented stereotactic approach to cerebrospinal fluid collection in mice. <i>Brain Research</i> , <b>2022</b> , 1774, 147706	3.7	0
201	Biology and pathophysiology of central nervous system metastases <b>2022</b> , 55-78		
200	Abstract P1-21-06: Phase I study of T-DM1 and metronomic temozolomide in secondary prevention of HER2+ breast cancer brain metastases following local radiation therapy. <i>Cancer Research</i> , <b>2022</b> , 82, P1-21-06-P1-21-06	10.1	
199	Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas.. <i>Nature Communications</i> , <b>2022</b> , 13, 1325	17.4	2
198	Tumor Immune Microenvironment of Brain Metastases: Toward Unlocking Antitumor Immunity.. <i>Cancer Discovery</i> , <b>2022</b> , OF1-OF17	24.4	1
197	Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. <i>Neuro-Oncology</i> , <b>2022</b> , 24, 331-357	1	0
196	Emerging Systemic Treatment Perspectives on Brain Metastases: Moving Toward a Better Outlook for Patients.. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2022</b> , 42, 1-19	7.1	0
195	Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2200333	2.2	0
194	Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , JCO210231422		
193	PATH-37. DISTINCT GENOMIC SUBCLASSES OF HIGH-GRADE/PROGRESSIVE MENINGIOMAS: NF2-ASSOCIATED, NF2-EXCLUSIVE, AND NF2-AGNOSTIC. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi123-vi123	1	
192	IMMU-02. GENOMIC AND TRANSCRIPTOMIC CORRELATES OF IMMUNOTHERAPY RESPONSE WITHIN THE TUMOR MICROENVIRONMENT OF LEPTOMENINGEAL METASTASES. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi92-vi92	1	
191	Precision medicine biomarkers in brain metastases: applications, discordances, and obstacles. <i>Neuro-Oncology Advances</i> , <b>2021</b> , 3, v35-v42	0.9	
190	Preclinical Solid Tumor Models to Study Novel Therapeutics in Brain Metastases. <i>Current Protocols</i> , <b>2021</b> , 1, e284		
189	CTIM-30. PHASE II TRIAL OF PEMBROLIZUMAB IN RECURRENT AND RESIDUAL HIGH-GRADE MENINGIOMAS. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi57-vi57	1	
188	DDRE-01. CDK PATHWAY INHIBITION WITH ABEMACICLIB IMPROVES INTRACRANIAL AND EXTRACRANIAL RESPONSE TO CHECKPOINT BLOCKADE IN PRE-CLINICAL MODELS OF MELANOMA BRAIN METASTASIS. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi74-vi74	1	
187	QOLP-01. EXPERIENCES FROM PATIENT, CAREGIVER, AND PHYSICIAN SURVEYS ON DIAGNOSIS AND TREATMENT OF BRAIN METASTASES. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi182-vi182	1	

186	BIOM-04. SENSITIVE DETECTION OF LEPTOMENINGEAL DISEASE USING CELL-FREE DNA FROM CEREBROSPINAL FLUID. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi10-vi10	1	
185	CTNI-53. RADIATION TREATMENT VOLUMES BEFORE AND AFTER BRAF/MEK THERAPY IN NEWLY DIAGNOSED PAPILLARY CRANIOPHARYNGIOMAS: A CORRELATIVE ANALYSIS OF THE ALLIANCE A071601 PHASE II TRIAL. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi72-vi72	1	
184	DDRE-03. THERAPEUTIC TARGETING OF THE ERK AND CDK PATHWAYS IN PRECLINICAL MODELS OF BRAIN METASTASES. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi74-vi75	1	
183	CTIM-01. PHASE II TRIAL OF PEMBROLIZUMAB AND LENVATINIB FOR LEPTOMENINGEAL METASTASES. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi48-vi49	1	
182	Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. <i>JAMA Oncology</i> , <b>2021</b> ,	13.4	6
181	Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. <i>Nature Communications</i> , <b>2021</b> , 12, 5954	17.4	7
180	Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases. <i>Nature Communications</i> , <b>2021</b> , 12, 5955	17.4	4
179	A rapid genotyping panel for detection of primary central nervous system lymphoma. <i>Blood</i> , <b>2021</b> , 138, 382-386	2.2	1
178	Anti-EGFR VHH-armed death receptor ligand-engineered allogeneic stem cells have therapeutic efficacy in diverse brain metastatic breast cancers. <i>Science Advances</i> , <b>2021</b> , 7,	14.3	1
177	Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. <i>Cell</i> , <b>2021</b> , 184, 1281-1298.e26	56.2	55
176	Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations.. <i>Nature Cancer</i> , <b>2021</b> , 2, 498-502	15.4	9
175	Evolution of delayed resistance to immunotherapy in a melanoma responder. <i>Nature Medicine</i> , <b>2021</b> , 27, 985-992	50.5	11
174	Leptomeningeal Metastases from Solid Tumors: Recent Advances in Diagnosis and Molecular Approaches. <i>Cancers</i> , <b>2021</b> , 13,	6.6	6
173	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors <b>2021</b> , 9,		20
172	Central Nervous System-Specific Outcomes of Phase 3 Randomized Clinical Trials in Patients With Advanced Breast Cancer, Lung Cancer, and Melanoma. <i>JAMA Oncology</i> , <b>2021</b> , 7, 1062-1064	13.4	5
171	DeepNeuro: an open-source deep learning toolbox for neuroimaging. <i>Neuroinformatics</i> , <b>2021</b> , 19, 127-140	5.02	11
170	Emerging Immunotherapies in the Treatment of Brain Metastases. <i>Oncologist</i> , <b>2021</b> , 26, 231-241	5.7	12
169	Craniopharyngiomas, including Recurrent Cases, Lack TERT Promoter Hotspot Mutations. <i>Neurologia Medico-Chirurgica</i> , <b>2021</b> , 61, 385-391	2.6	0

168	Sporadic multiple meningiomas harbor distinct driver mutations. <i>Acta Neuropathologica Communications</i> , <b>2021</b> , 9, 8	7.3	2
167	Clinical significance of checkpoint regulator "Programmed death ligand-1 (PD-L1)" expression in meningioma: review of the current status. <i>Journal of Neuro-Oncology</i> , <b>2021</b> , 151, 443-449	4.8	3
166	A broad perspective on evaluating bias in the neuro-oncology workplace. <i>Neuro-Oncology</i> , <b>2021</b> , 23, 498-499		0
165	Cross-sectional survey of patients, caregivers, and physicians on diagnosis and treatment of brain metastases. <i>Neuro-Oncology Practice</i> , <b>2021</b> , 8, 662-673	2.2	0
164	Detection of Leptomeningeal Disease Using Cell-Free DNA From Cerebrospinal Fluid. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2120040	10.4	6
163	IMMU-08. PHASE II TRIAL OF PEMBROLIZUMAB AND LENVATINIB FOR LEPTOMENINGEAL METASTASES. <i>Neuro-Oncology Advances</i> , <b>2021</b> , 3, iv6-iv6	0.9	
162	Molecular profiling of pediatric meningiomas shows tumor characteristics distinct from adult meningiomas. <i>Acta Neuropathologica</i> , <b>2021</b> , 142, 873-886	14.3	1
161	CTIM-02. PHASE II STUDY OF IPILIMUMAB AND NIVOLUMAB IN LEPTOMENINGEAL CARCINOMATOSIS. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi49-vi49	1	
160	PATH-40. SPORADIC NF2 WILD-TYPE MULTIPLE MENINGIOMAS HARBOR DISTINCT DRIVER MUTATIONS. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi124-vi124	1	
159	HIF1A signaling selectively supports proliferation of breast cancer in the brain. <i>Nature Communications</i> , <b>2020</b> , 11, 6311	17.4	13
158	Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features. <i>Acta Neuropathologica</i> , <b>2020</b> , 140, 89-93	14.3	10
157	Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. <i>Nature Medicine</i> , <b>2020</b> , 26, 1280-1284	50.5	34
156	Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases. <i>Future Oncology</i> , <b>2020</b> , 16, 899-909	3.6	13
155	Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. <i>Nature Genetics</i> , <b>2020</b> , 52, 371-377	36.3	78
154	Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2020</b> , 91, 378-387	5.5	38
153	Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 757-772	1	45
152	Subtype switching in breast cancer brain metastases: a multicenter analysis. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 1173-1181	1	31
151	Systemic therapy following craniotomy in patients with a solitary breast cancer brain metastasis. <i>Breast Cancer Research and Treatment</i> , <b>2020</b> , 180, 147-155	4.4	4

150	Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions. <i>Pigment Cell and Melanoma Research</i> , <b>2020</b> , 33, 527-541	4.5	21
149	Brain Metastases from Biliary Tract Cancers: A Case Series and Review of the Literature in the Genomic Era. <i>Oncologist</i> , <b>2020</b> , 25, 447-453	5.7	1
148	Assessment of Effectiveness and Safety of Osimertinib for Patients With Intracranial Metastatic Disease: A Systematic Review and Meta-analysis. <i>JAMA Network Open</i> , <b>2020</b> , 3, e201617	10.4	16
147	DDRE-02. THERAPEUTIC TARGETING OF BRAIN METASTASIS WITH ERK INHIBITOR LY3214996 USING A NOVEL IN VIVO MODEL OF LUNG-TO-BRAIN METASTASIS. <i>Neuro-Oncology</i> , <b>2020</b> , 22, ii61-ii61	1	0
146	IMMU-01. SINGLE CELL SEQUENCING OF MELANOMA BRAIN METASTASES UNVEILS HETEROGENEITY OF THE TUMOR MICROENVIRONMENT IN RESPONSE TO IMMUNE CHECKPOINT BLOCKADE. <i>Neuro-Oncology</i> , <b>2020</b> , 22, ii104-ii104	1	0
145	TMOD-05. EXTRACRANIAL TUMORS INFLUENCE INTRACRANIAL RESPONSE TO IMMUNE CHECKPOINT INHIBITORS IN PRE-CLINICAL MODELS OF MELANOMA BRAIN METASTASIS. <i>Neuro-Oncology</i> , <b>2020</b> , 22, ii228-ii228	1	
144	NIMG-05. ADVANCED IMAGING TO ASSESS LONGITUDINAL VASCULAR CHANGES IN BRAIN METASTASES TREATED WITH CHECKPOINT INHIBITION. <i>Neuro-Oncology</i> , <b>2020</b> , 22, ii147-ii147	1	
143	PATH-40. INTRAGENIC DMD DELETIONS ARE THE MOST COMMON RECURRENT GENOMIC ALTERATIONS IN ESTHESIONEUROBLASTOMA. <i>Neuro-Oncology</i> , <b>2020</b> , 22, ii173-ii173	1	
142	BIOM-54. A RAPID GENOTYPING PANEL FOR SENSITIVE AND SPECIFIC SEGREGATION OF CNS PATHOLOGIES. <i>Neuro-Oncology</i> , <b>2020</b> , 22, ii13-ii13	1	
141	Genomic Characterization of Brain Metastases: Implications for Precision Medicine <b>2020</b> , 43-58		
140	Role of Precision Medicine in Patients with CNS Metastasis <b>2020</b> , 69-82		
139	Emerging Meningioma Therapies II: Immunotherapies, Novel Radiotherapy Techniques, and Other Experimental Approaches <b>2020</b> , 227-238		
138	Neurologic complications of melanoma. <i>Cancer</i> , <b>2020</b> , 126, 477-486	6.4	
137	Brain metastasis. <i>Nature Reviews Cancer</i> , <b>2020</b> , 20, 4-11	31.3	77
136	04. ASSESSMENT OF EFFICACY AND SAFETY OF OSIMERTINIB FOR PATIENTS WITH INTRACRANIAL METASTATIC DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS. <i>Neuro-Oncology Advances</i> , <b>2020</b> , 2, ii1-ii1	0.9	78
135	62. PRESENCE OF EXTRACRANIAL TUMORS INFLUENCES RESPONSE TO IMMUNE CHECKPOINT INHIBITORS IN A PRE-CLINICAL MODEL OF MELANOMA BRAIN METASTASIS. <i>Neuro-Oncology Advances</i> , <b>2020</b> , 2, ii13-ii13	0.9	1
134	Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic. <i>Acta Neuropathologica Communications</i> , <b>2020</b> , 8, 171	7.3	18
133	Pervasive chromosomal instability and karyotype order in tumour evolution. <i>Nature</i> , <b>2020</b> , 587, 126-132	50.4	67

132	Response to Letter to Editor. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 1706-1707	1	1
131	Initial Approach to the Patient with Multiple Newly Diagnosed Brain Metastases. <i>Neurosurgery Clinics of North America</i> , <b>2020</b> , 31, 505-513	4	
130	Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons. <i>Neurosurgery</i> , <b>2020</b> , 87, E281-E288	3.2	6
129	Concurrent therapy with immune checkpoint inhibitors and TNF blockade in patients with gastrointestinal immune-related adverse events <b>2019</b> , 7, 226		52
128	Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 571-584	1	67
127	Genomic Analysis of Posterior Fossa Meningioma Demonstrates Frequent Mutations in Foramen Magnum Meningiomas. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , <b>2019</b> , 80, 562-567	1.5	8
126	Advances in multidisciplinary therapy for meningiomas. <i>Neuro-Oncology</i> , <b>2019</b> , 21, i18-i31	1	44
125	DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 901-910	1	79
124	Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 1401-1411	1	40
123	Precision Medical Approaches to the Diagnoses and Management of Brain Metastases. <i>Current Treatment Options in Oncology</i> , <b>2019</b> , 20, 49	5.4	5
122	Modern Management of Central Nervous System Metastases in the Era of Targeted Therapy and Immune Oncology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2019</b> , 39, e59-e69	7.1	6
121	Clinical Validation of a Cell-Free DNA Gene Panel. <i>Journal of Molecular Diagnostics</i> , <b>2019</b> , 21, 632-645	5.1	9
120	Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 424-427	1	14
119	Targeting Molecular Pathways in Intracranial Metastatic Disease. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 99	5.3	7
118	Increased risk of brain metastases in ovarian cancer patients with BRCA mutations. <i>Gynecologic Oncology</i> , <b>2019</b> , 153, 568-573	4.9	21
117	Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1130-1135	2.2	12
116	The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in -Mutant Breast Cancer Brain Metastases. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 3374-3383	12.9	34
115	Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations. <i>Cancer</i> , <b>2019</b> , 125, 2910-2914	6.4	28

114	An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. <i>Cell</i> , <b>2019</b> , 178, 835-849	21	556
113	A Monoclonal Antibody Against $\alpha$ 5 $\beta$ 1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma. <i>Targeted Oncology</i> , <b>2019</b> , 14, 479-489	5	5
112	The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 1498-1508	1	25
111	Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors <b>2019</b> , 7, 265		37
110	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Surgery in the Management of Adults With Metastatic Brain Tumors. <i>Neurosurgery</i> , <b>2019</b> , 84, E152-E155	32	62
109	Genomic characterization of lung tumors and metastatic (Met) sites in advanced (Adv) NSCLC.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2014-2014	2.2	2
108	Clinical characteristics, treatment (Tx) patterns, and overall survival (OS) in advanced (Adv) NSCLC patients (Pts) with and without brain metastases (BM).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2035-2035	2.2	
107	INNV-27. THE IMPACT OF A DEDICATED MULTIDISCIPLINARY TUMOR BOARD ON CARE FOR PATIENTS WITH BRAIN METASTASES. <i>Neuro-Oncology</i> , <b>2019</b> , 21, vi135-vi136	1	1
106	RARE-04. TARGETED TREATMENT OF PAPILLARY CRANIOPHARYNGIOMAS HARBORING BRAFV600E MUTATIONS. <i>Neuro-Oncology</i> , <b>2019</b> , 21, vi222-vi222	1	78
105	NIMG-43. LONGITUDINAL TRACKING AND GROWTH RATE CHARACTERIZATION OF BRAIN METASTASES ON MAGNETIC RESONANCE IMAGING. <i>Neuro-Oncology</i> , <b>2019</b> , 21, vi170-vi171	1	78
104	Enrichment of Amplification in Brain Metastases from Primary Gastrointestinal Malignancies. <i>Oncologist</i> , <b>2019</b> , 24, 193-201	5.7	5
103	Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control. <i>Oncologist</i> , <b>2019</b> , 24, 671-679	5.7	19
102	L265P mutation and loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. <i>Blood Advances</i> , <b>2019</b> , 3, 375-383	7.8	40
101	TMOD-24. DEVELOPMENT OF A NOVEL IN VIVO MODEL OF LUNG-TO-BRAIN METASTASIS PROGRESSION. <i>Neuro-Oncology</i> , <b>2019</b> , 21, vi267-vi268	1	78
100	INNV-19. SURVEYING BIAS IN NEURO-ONCOLOGY AND SOCIETY FOR NEURO ONCOLOGY (SNO) MEMBERS: GENDER AND BEYOND. <i>Neuro-Oncology</i> , <b>2019</b> , 21, vi134-vi134	1	1
99	GENE-63. GENOMIC CHARACTERIZATION OF HUMAN BRAIN METASTASES IDENTIFIES NOVEL DRIVERS OF LUNG ADENOCARCINOMA PROGRESSION. <i>Neuro-Oncology</i> , <b>2019</b> , 21, vi111-vi111	1	78
98	Longitudinal molecular trajectories of diffuse glioma in adults. <i>Nature</i> , <b>2019</b> , 576, 112-120	50.4	151
97	The impact of histopathology and NAB2-STAT6 fusion subtype in classification and grading of meningeal solitary fibrous tumor/hemangiopericytoma. <i>Acta Neuropathologica</i> , <b>2019</b> , 137, 307-319	14.3	28

96	Life after surgical resection of a meningioma: a prospective cross-sectional study evaluating health-related quality of life. <i>Neuro-Oncology</i> , <b>2019</b> , 21, i32-i43	1	33
95	Imaging and diagnostic advances for intracranial meningiomas. <i>Neuro-Oncology</i> , <b>2019</b> , 21, i44-i61	1	55
94	Molecular and translational advances in meningiomas. <i>Neuro-Oncology</i> , <b>2019</b> , 21, i4-i17	1	46
93	A Clinical Rule for Preoperative Prediction of BRAF Mutation Status in Craniopharyngiomas. <i>Neurosurgery</i> , <b>2019</b> , 85, 204-210	3.2	17
92	The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort. <i>European Urology Focus</i> , <b>2019</b> , 5, 474-481	5.1	27
91	A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases. <i>Cell</i> , <b>2018</b> , 172, 1050-1062.e14	4.2	46
90	The Evolving Landscape of Brain Metastasis. <i>Trends in Cancer</i> , <b>2018</b> , 4, 176-196	12.5	110
89	Advances in meningioma genetics: novel therapeutic opportunities. <i>Nature Reviews Neurology</i> , <b>2018</b> , 14, 106-115	15	80
88	Emerging Gene Fusion Drivers in Primary and Metastatic Central Nervous System Malignancies: A Review of Available Evidence for Systemic Targeted Therapies. <i>Oncologist</i> , <b>2018</b> , 23, 1063-1075	5.7	8
87	Toward Precision Medicine in Brain Metastases. <i>Seminars in Neurology</i> , <b>2018</b> , 38, 95-103	3.2	4
86	Genotype-targeted local therapy of glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, E8388-E8394	11.5	29
85	NFM-11. PEDIATRIC MENINGIOMAS ARE MOLECULARLY DISTINCT FROM ADULT COUNTERPARTS. <i>Neuro-Oncology</i> , <b>2018</b> , 20, i144-i145	1	1
84	Reactive astrocytic S1P3 signaling modulates the blood-tumor barrier in brain metastases. <i>Nature Communications</i> , <b>2018</b> , 9, 2705	17.4	62
83	TERT Alterations in Progressive Treatment-Resistant Meningiomas. <i>Neurosurgery</i> , <b>2018</b> , 65, 66-68	3.2	5
82	DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. <i>Acta Neuropathologica</i> , <b>2018</b> , 136, 779-792	14.3	41
81	Brain metastasis from squamous cell carcinoma of the head and neck: a review of the literature in the genomic era. <i>Neurosurgical Focus</i> , <b>2018</b> , 44, E11	4.2	10
80	Profiles of brain metastases: Prioritization of therapeutic targets. <i>International Journal of Cancer</i> , <b>2018</b> , 143, 3019-3026	7.5	17
79	Phase II study of pembrolizumab in leptomeningeal carcinomatosis.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2007-2007	2.2	16



78	Recent advances in managing brain metastasis. <i>F1000Research</i> , <b>2018</b> , 7,	3.6	32
77	HER2 positivity in brain metastases from gastrointestinal primary malignancies.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 61-61	2.2	0
76	MYD88 L265P mutation and CDKN2A loss as early mutational events in primary central nervous system lymphomas.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e14041-e14041	2.2	0
75	TERT rearrangements to identify a subset of aggressive meningiomas.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e14028-e14028	2.2	1
74	Leptomeningeal metastasis from systemic cancer: Review and update on management. <i>Cancer</i> , <b>2018</b> , 124, 21-35	6.4	105
73	Precision Medicine for Primary Central Nervous System Tumors: Are We There Yet?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2018</b> , 38, 158-167	7.1	4
72	New molecular targets in meningiomas: the present and the future. <i>Current Opinion in Neurology</i> , <b>2018</b> , 31, 740-746	7.1	6
71	CMET-20. EVIDENCE OF CNS RESPONSE OF PEMBROLIZUMAB FOR LEPTOMENINGEAL CARCINOMATOSIS AT A SINGLE CELL RESOLUTION. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi57-vi58	1	1
70	GENE-18. DIVERGENT CLONAL EVOLUTION OF MELANOMA BRAIN METASTASES DURING TREATMENT WITH IMMUNOTHERAPY. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi106-vi107	1	78
69	Seminoma with Neoplastic Meningitis Treated with Craniospinal Irradiation. <i>Oncologist</i> , <b>2018</b> , 23, 1385-1387	3.7	1
68	CMET-16. THE ROLE OF SURGICAL RESECTION OF MELANOMA BRAIN METASTASES IN THE IMMUNOTHERAPY ERA. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi56-vi57	1	78
67	Updates in prognostic markers for gliomas. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vii17-vii26	1	51
66	CSIG-29. THE DUAL PI3K/mTOR-PATHWAY INHIBITOR GDC-0084 ACHIEVES ANTITUMOR ACTIVITY IN BREAST CANCER BRAIN METASTASES IN VITRO AND IN VIVO. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi49-vi49	1	1
65	Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine. <i>CNS Oncology</i> , <b>2017</b> , 6, 139-151	4	7
64	Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas. <i>Journal of Neurosurgery</i> , <b>2017</b> , 127, 438-444	3.2	31
63	Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. <i>Science</i> , <b>2017</b> , 355,	33.3	455
62	Atypical and Malignant Meningiomas <b>2017</b> , 856-870		
61	Sequencing brain metastases and opportunities for targeted therapies. <i>Pharmacogenomics</i> , <b>2017</b> , 18, 585-594	2.6	5

60	Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. <i>Neuro-Oncology</i> , <b>2017</b> , 19, 535-545	1	60
59	Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 6650-6660	12.9	104
58	Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. <i>Npj Precision Oncology</i> , <b>2017</b> , 1, 5	9.8	37
57	SMO mutant olfactory groove meningiomas-the next in line for targeted therapy. <i>Neuro-Oncology</i> , <b>2017</b> , 19, 305-306	1	1
56	Treatment of brain metastases in the modern genomic era. <i>Pharmacology &amp; Therapeutics</i> , <b>2017</b> , 170, 64-72	13.9	32
55	Landscape of Genomic Alterations in Pituitary Adenomas. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 1841-1851	12.9	64
54	Resolving the phylogenetic origin of glioblastoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimens. <i>Npj Precision Oncology</i> , <b>2017</b> , 1, 33	9.8	17
53	CMET-16. THE ROLE OF SURGICAL RESECTION OF MELANOMA BRAIN METASTASES IN THE IMMUNOTHERAPY ERA. <i>Neuro-Oncology</i> , <b>2017</b> , 19, vi42-vi42	1	78
52	Genetic Characterization of Brain Metastases in the Era of Targeted Therapy. <i>Frontiers in Oncology</i> , <b>2017</b> , 7, 230	5.3	31
51	Intratumoral heterogeneity and promoter mutations in progressive/higher-grade meningiomas. <i>Oncotarget</i> , <b>2017</b> , 8, 109228-109237	3.3	61
50	Clinically-actionable Mutations in Posterior Skull Base Meningiomas. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , <b>2017</b> , 78, S1-S156	1.5	1
49	Contemporary incidence and epidemiologic trends of brain metastases at renal cell carcinoma diagnosis.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 529-529	2.2	
48	TERT promoter mutations in progressive treatment-resistant meningiomas.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2047-2047	2.2	2
47	Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 2027-2032	8.9	75
46	Melanoma central nervous system metastases: current approaches, challenges, and opportunities. <i>Pigment Cell and Melanoma Research</i> , <b>2016</b> , 29, 627-642	4.5	74
45	Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 256-60	8.9	45
44	Management of Brain Metastases in Patients With Melanoma. <i>Journal of Oncology Practice</i> , <b>2016</b> , 12, 536-42	3.1	25
43	: meningioma. <i>Neuro-Oncology Practice</i> , <b>2016</b> , 3, 120-134	2.2	4

42	A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 1278-87	1	12
41	Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 649-55	1	144
40	Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108,	9.7	144
39	BRAF alteration status and the histone H3F3A gene K27M mutation segregate spinal cord astrocytoma histology. <i>Acta Neuropathologica</i> , <b>2016</b> , 131, 147-50	14.3	48
38	Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy. <i>Neurosurgical Focus</i> , <b>2016</b> , 41, E2	4.2	19
37	ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma. <i>European Journal of Endocrinology</i> , <b>2016</b> , 174, R139-44	6.5	41
36	Brain Metastasis: Clinical Implications of Branched Evolution. <i>Trends in Cancer</i> , <b>2016</b> , 2, 332-337	12.5	15
35	Alterations in Pericyte Subpopulations Are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 5287-5299	12.9	98
34	Novel approaches in genetic characterization and targeted therapy for brain metastases. <i>Discovery Medicine</i> , <b>2016</b> , 22, 237-250	2.5	5
33	Molecular typing of Meningiomas by Desorption Electrospray Ionization Mass Spectrometry Imaging for Surgical Decision-Making. <i>International Journal of Mass Spectrometry</i> , <b>2015</b> , 377, 690-698	1.9	38
32	PLEKHA5: A Key to Unlock the Blood-Brain Barrier?. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 1978-80	12.9	10
31	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. <i>Cancer Discovery</i> , <b>2015</b> , 5, 1164-1177	24.4	581
30	Rapid Intraoperative Molecular Characterization of Glioma. <i>JAMA Oncology</i> , <b>2015</b> , 1, 662-7	13.4	53
29	Ipilimumab and craniotomy in patients with melanoma and brain metastases: a case series. <i>Neurosurgical Focus</i> , <b>2015</b> , 38, E5	4.2	16
28	Systemic therapy of brain metastases. <i>Current Neurology and Neuroscience Reports</i> , <b>2015</b> , 15, 518	6.6	27
27	Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. <i>Oncotarget</i> , <b>2015</b> , 6, 4704-16	3.3	92
26	Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 232-6	8.9	124
25	BMET-04LEPTOMENINGEAL CARCINOMATOSIS IN MELANOMA. <i>Neuro-Oncology</i> , <b>2015</b> , 17, v45.4-v45	1	78

24	Genomic profiling of brain metastases: current knowledge and new frontiers. <i>Chinese Clinical Oncology</i> , <b>2015</b> , 4, 22	2.3	13
23	Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. <i>Nature Genetics</i> , <b>2014</b> , 46, 161-5	36.3	320
22	Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S. <i>Nature Cell Biology</i> , <b>2014</b> , 16, 876-88	23.4	227
21	Turner syndrome and meningioma: support for a possible increased risk of neoplasia in Turner syndrome. <i>European Journal of Medical Genetics</i> , <b>2014</b> , 57, 269-74	2.6	13
20	Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. <i>Oncotarget</i> , <b>2014</b> , 5, 10596-606	3.3	46
19	Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues. <i>Acta Neuropathologica</i> , <b>2014</b> , 128, 879-91	14.3	46
18	Sporadic hemangioblastomas are characterized by cryptic VHL inactivation. <i>Acta Neuropathologica Communications</i> , <b>2014</b> , 2, 167	7.3	45
17	Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. <i>Nature Genetics</i> , <b>2013</b> , 45, 285-9	36.3	397
16	Radiation Treatment for WHO Grade II and III Meningiomas. <i>Frontiers in Oncology</i> , <b>2013</b> , 3, 227	5.3	56
15	Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 8188-93	11.5	156
14	Clinical discussion and review of the management of brain metastases. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2013</b> , 11, 1153-64	7.3	36
13	The toxicity of intrathecal bevacizumab in a rabbit model of leptomeningeal carcinomatosis. <i>Journal of Neuro-Oncology</i> , <b>2012</b> , 106, 81-8	4.8	14
12	Primary central nervous system lymphoma: overview of current treatment strategies. <i>Hematology/Oncology Clinics of North America</i> , <b>2012</b> , 26, 897-916	3.1	27
11	Kairos. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1562	2.2	1
10	Leptomeningeal Metastasis <b>2012</b> , 187-200		1
9	Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis. <i>Journal of Neuro-Oncology</i> , <b>2011</b> , 105, 325-35	4.8	58
8	Vascular endothelial growth factor inhibitors in malignant gliomas. <i>Targeted Oncology</i> , <b>2010</b> , 5, 167-74	5	9
7	Wiped out. <i>American Journal of Medicine</i> , <b>2009</b> , 122, 1004-6	2.4	1

6	Aneurysmal bone cysts of the sacrum: a report of ten cases and review of the literature. <i>Iowa orthopaedic journal, The</i> , <b>2009</b> , 29, 74-8	1.1	19
5	VEGF inhibitors in brain tumors. <i>Clinical Advances in Hematology and Oncology</i> , <b>2009</b> , 7, 753-60, 768	0.6	7
4	Tuberculosis-associated haemophagocytic syndrome. <i>Lancet Infectious Diseases, The</i> , <b>2006</b> , 6, 447-54	25.5	119
3	Solitary thoracic osteochondroma: case report and review of the literature. <i>Neurosurgery</i> , <b>2005</b> , 56, E1379; discussion E1379	3.2	25
2	A novel intravertebral tumor model in rabbits. <i>Neurosurgery</i> , <b>2005</b> , 57, 341-6; discussion 341-6	3.2	19
1	Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors		3